Abstract
Summary
The global Drugs for Duchenne Muscular Dystrophy (DMD) market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Drugs for Duchenne Muscular Dystrophy (DMD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Drugs for Duchenne Muscular Dystrophy (DMD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Drugs for Duchenne Muscular Dystrophy (DMD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Drugs for Duchenne Muscular Dystrophy (DMD) players cover Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals and WaVe life Science, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Drugs for Duchenne Muscular Dystrophy (DMD) Industry Forecast” looks at past sales and reviews total world Drugs for Duchenne Muscular Dystrophy (DMD) sales in 2022, providing a comprehensive analysis by region and market sector of projected Drugs for Duchenne Muscular Dystrophy (DMD) sales for 2023 through 2029. With Drugs for Duchenne Muscular Dystrophy (DMD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for Duchenne Muscular Dystrophy (DMD) industry.
This Insight Report provides a comprehensive analysis of the global Drugs for Duchenne Muscular Dystrophy (DMD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for Duchenne Muscular Dystrophy (DMD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drugs for Duchenne Muscular Dystrophy (DMD) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Duchenne Muscular Dystrophy (DMD) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Duchenne Muscular Dystrophy (DMD).
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Duchenne Muscular Dystrophy (DMD) market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Eteplirsen
Deflazacort
Ataluren
Segmentation by application
Hospitals
Clinics
Home Care
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
WaVe life Science
United States market for Drugs for Duchenne Muscular Dystrophy (DMD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Drugs for Duchenne Muscular Dystrophy (DMD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Drugs for Duchenne Muscular Dystrophy (DMD) is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Drugs for Duchenne Muscular Dystrophy (DMD) players cover Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals and WaVe life Science, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Drugs for Duchenne Muscular Dystrophy (DMD) Industry Forecast” looks at past sales and reviews total world Drugs for Duchenne Muscular Dystrophy (DMD) sales in 2022, providing a comprehensive analysis by region and market sector of projected Drugs for Duchenne Muscular Dystrophy (DMD) sales for 2023 through 2029. With Drugs for Duchenne Muscular Dystrophy (DMD) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drugs for Duchenne Muscular Dystrophy (DMD) industry.
This Insight Report provides a comprehensive analysis of the global Drugs for Duchenne Muscular Dystrophy (DMD) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Drugs for Duchenne Muscular Dystrophy (DMD) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Drugs for Duchenne Muscular Dystrophy (DMD) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drugs for Duchenne Muscular Dystrophy (DMD) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drugs for Duchenne Muscular Dystrophy (DMD).
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs for Duchenne Muscular Dystrophy (DMD) market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Eteplirsen
Deflazacort
Ataluren
Segmentation by application
Hospitals
Clinics
Home Care
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
WaVe life Science
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size 2018-2029
2.1.2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type
2.2.1 Eteplirsen
2.2.2 Deflazacort
2.2.3 Ataluren
2.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type
2.3.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type (2018-2023)
2.4 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Home Care
2.5 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
2.5.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Application (2018-2023)
3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Player
3.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Players
3.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue by Players (2018-2023)
3.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Players (2018-2023)
3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Drugs for Duchenne Muscular Dystrophy (DMD) by Regions
4.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Regions (2018-2023)
4.2 Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth (2018-2023)
4.3 APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth (2018-2023)
4.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth (2018-2023)
4.5 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Growth (2018-2023)
5 Americas
5.1 Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2018-2023)
5.2 Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2018-2023)
5.3 Americas Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region (2018-2023)
6.2 APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2018-2023)
6.3 APAC Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) by Country (2018-2023)
7.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2018-2023)
7.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) by Region (2018-2023)
8.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (2018-2023)
8.3 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecast by Regions (2024-2029)
10.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecast by Regions (2024-2029)
10.1.2 Americas Drugs for Duchenne Muscular Dystrophy (DMD) Forecast
10.1.3 APAC Drugs for Duchenne Muscular Dystrophy (DMD) Forecast
10.1.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Forecast
10.1.5 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Forecast
10.2 Americas Drugs for Duchenne Muscular Dystrophy (DMD) Forecast by Country (2024-2029)
10.2.1 United States Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.2.2 Canada Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.2.3 Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.2.4 Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.3 APAC Drugs for Duchenne Muscular Dystrophy (DMD) Forecast by Region (2024-2029)
10.3.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.3.2 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.3.3 Korea Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.3.4 Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.3.5 India Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.3.6 Australia Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Forecast by Country (2024-2029)
10.4.1 Germany Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.4.2 France Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.4.3 UK Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.4.4 Italy Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.4.5 Russia Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.5 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Forecast by Region (2024-2029)
10.5.1 Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.5.2 South Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.5.3 Israel Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.5.4 Turkey Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.5.5 GCC Countries Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast
10.6 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecast by Type (2024-2029)
10.7 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Information
11.1.2 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Sarepta Therapeutics Main Business Overview
11.1.5 Sarepta Therapeutics Latest Developments
11.2 PTC Therapeutics
11.2.1 PTC Therapeutics Company Information
11.2.2 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.2.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 PTC Therapeutics Main Business Overview
11.2.5 PTC Therapeutics Latest Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.3.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Pfizer Main Business Overview
11.3.5 Pfizer Latest Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Information
11.4.2 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.4.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Bristol-Myers Squibb Main Business Overview
11.4.5 Bristol-Myers Squibb Latest Developments
11.5 Italfarmaco
11.5.1 Italfarmaco Company Information
11.5.2 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.5.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Italfarmaco Main Business Overview
11.5.5 Italfarmaco Latest Developments
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Information
11.6.2 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Santhera Pharmaceuticals Main Business Overview
11.6.5 Santhera Pharmaceuticals Latest Developments
11.7 WaVe life Science
11.7.1 WaVe life Science Company Information
11.7.2 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Offered
11.7.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 WaVe life Science Main Business Overview
11.7.5 WaVe life Science Latest Developments
12 Research Findings and Conclusion